Imatinib mesylate and the management of chronic myeloid leukemia (CML)Ebru Koca, İbrahim C. HaznedaroğluDepartment Of Internal Medicine, Hematology Unit, Hacettepe University School Of Medicine, Ankara, Turkey Keywords: Chronic myeloid leukemia (CML), Imatinib mesylate, BCR-ABL, Signal transduction inhibitor.
Ebru Koca, İbrahim C. Haznedaroğlu. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol. 2005; 22(4): 161-172
Corresponding Author: İbrahim C. Haznedaroğlu, Türkiye |
|